Findings
========

CLL (Chronic lymphocytic leukemia) is an incurable disease mainly affecting the B cell lineage in the western population, with a median age of diagnosis of 72 year old \[[@B1]\]. Determining the cause of CLL is crucial for understanding the acquisition and for clinical diagnosis, treatment and prognosis of CLL. Genetic factors have been linked to the etiology of CLL. Cytogenetic analyses identified chromosomal abnormalities including del11q23 affecting the *ATM*gene, tri12, del 13q14, and del17p13 affecting *TP53*gene \[[@B2]\]. In addition, CGH studies found gains and losses in Xp11.2-p21 and Xq21-qter \[[@B3]\]. Molecular studies identified three genes: *IgVH*, *CD38*and *ZAP-70*that correlate with CLL prognosis \[[@B4]-[@B6]\]. A CLL-specific microRNA signature was also identified, suggesting that microRNA deletion could be involved in CLL \[[@B7]\]. SNP array studies identified 2q21.2, 6p22.1 and 18q21.1 abnormalities that follow a Mendelian inheritance pattern \[[@B8]\]. Whole genome association studies also identified multiple loci at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 that appear to be associated with genetic susceptibility to CLL \[[@B9]\].

Although evidence supports the involvement of genetic factors in CLL, the frequency of genomic aberrations identified in CLL is relatively lower than those observed in the leukemias affecting other types of hematopoietic lineages \[[@B10]\]. This information suggests that the CLL genome is relatively intact with fewer aberrations than other types of leukemia. Alternatively, more genomic aberrations may exist in CLL but these could mainly be small lesions in the CLL genome that are difficult to detect using conventional technologies due to their limited resolution. With the rapid progress of genome sequencing technologies, enthusiasm is increasing for pursuing comprehensive detection of genomic aberrations in cancer by sequencing cancer genomes. In the case of CLL, a critical issue is to know the degree of genomic aberrations in order to justify the use of whole genome sequencing approach to analyze CLL genome. We reasoned if we can scan certain CLL genomes at sufficient high resolution and at reasonable genome coverage, we should gain first-hand information to estimate the degree of genomic aberrations in CLL.

We recently developed the DGS (Ditag Genome Scanning) technique that uses next-generation DNA sequencing technologies to collect paired-end sequences from restriction DNA fragments across a genome \[[@B11]\]. Using this technique, we analyzed CLL genomes. Nine samples of peripheral blood from untreated CLL patients diagnosed in Northwestern University Lurie Cancer Center and University of Chicago Medical Center were used in this study, of which three were used for paired-end tag collection, and eight including two used in paired-end tag collection were used for full-length sequencing analysis (Additional file [1](#S1){ref-type="supplementary-material"}: Supplemental Table S1). Informed consent was made by the patients, and the use of clinical CLL samples was approved by the institutional review board of University of Chicago and Northwestern University following institutional guidelines. The detailed experimental process followed the published protocol \[[@B11]\] and outlined in Figure [1](#F1){ref-type="fig"}. Briefly, mononuclear cells were isolated from each CLL peripheral blood or bone marrow sample by using NycoPrep™ A solution (Axis-Shield). Human genomic DNA was extracted from mononuclear cells by using QIAamp DNA Blood Kit (QIAGEN) following the manufacturer\'s protocol. To generate the DGS library, genomic DNA was fractionated by *HindIII*restriction digestion. The restriction fragments were dephosphorylated by CIP and cloned into pDGS-*HindIII*vector that contains two *MmeI*sites next to the *HindIII*cloning site. The genomic library was digested by *MmeI*to release two tags from the cloned DNA fragments. The tag-vector-tag fragments were then gel-purified, and re-ligated to form a ditag library. Ditags were released from the vectors by *HindIII*digestion, gel-purified, and concatemerized by using T4 DNA ligase (Promega). The concatemers at 200 to 500 bps were agarose-gel-purified and used for ditag sequencing by using a 454 GS20 sequencer (454 Life Sciences). Ditags were extracted from the resulting sequences based on the *HindIII*sites. Same ditags were combined to generate a unique ditag with the corresponding copy numbers.

![**Outline of the experimental process**. Genomic DNA samples were digested by restriction enzymes. Ditags (paired-end tags) were collected from both ends of restriction fragments and sequenced. The ditag sequences were compared to known human reference genome sequences. The unmapped ditags were used as sense and antisense PCR primers to amplify their original DNA fragments to generate full-length sequences. The sequences were mapped to reference genome sequences to determine the type of genomic aberrations.](1756-0500-3-341-1){#F1}

To generate the reference ditag database, virtual *HindIII*restriction fragments were generated from known human genomic sequences. Two 16-bp virtual tags were extracted from the 5\' and the 3\' ends of each virtual fragment, and connected to form a reference ditag representing the virtual DNA fragment. The following sequences were used to extract the reference ditags:

1\. Human genome reference sequences (hg18): <http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/>

2\. Human dbSNP 126: <ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606>

3\. Chimpanzee genome reference sequences (PanTro2): <http://hgdownload.cse.ucsc.edu/goldenPath/panTro2/bigZips/>

4\. Human GM15510 fosmid paired-end sequences:

<http://www.ncbi.nlm.nih.gov/Traces/trace.cgi?&cmd=retrieve&val=CENTER_PROJECT%20%3D%20%22G248%22&size=0&retrieve=Submit>

5\. Celera human genome sequences: <http://www.ncbi.nlm.nih.gov/genomeprj/1431>

6\. Venter genome sequences: <ftp://ftp.ncbi.nih.gov/pub/TraceDB/Personal_Genomics/Venter/>

7\. Watson genome sequences: <ftp://ftp.ncbi.nih.gov/pub/TraceDB/Personal_Genomics/Watson/>

8\. Reference ditags were also extracted from *HindIII*fragments of E.coli K12 genome sequences to eliminate the ditags from E. coli DNA contaminated during library construction process.

Initial ditag mapping was performed with perfect match between experimental ditags and hg18 reference ditags. For the unmapped experimental ditags, a single-base mismatch in each single tag of the ditag was allowed to compensate for possible sequencing error or SNP. To identify the unmapped ditags related with homopolymer generated by 454 sequencing chemistry, the unmapped ditags with more than two homo-bases were stretched, e.g. AAA -\> AAAA, or shortened, e.g. AAA -\> AA, and mapped to reference ditags again. For the ditags remaining unmapped, they were mapped to the reference ditags of other sequence sources in the ditag reference database. The ditags remaining unmapped after these processes were defined as the unmapped ditags.

Unmapped ditag sequences were used to design sense primers and antisense (reverse/complementary) primers, with four extra bases CAGC added to the 5\' end of sense primer and CGCC to the 5\' end of antisense primer. Genomic DNA digested by *HindIII*was used as the templates for PCR amplification. PCR was performed with 35 cycles at 95°C 30 sec, 57°C 60 sec, and 72°C 3 min, followed by extension at 72°C for 10 min. The amplified products in each reaction were cloned into pGEM-T vector (Promega), transformed into E. coli TOP10 (Invitrogen), and plated in a single well of the 48-well Qtrays (Genetix). Four clones from each transformation were amplified by colony-PCR using M13F and M13R primers, and sequenced by Big-Dye Terminator v3.1 Cycle Sequencing Kit (ABI) using M13F primer. For the sequences that did not reach the full-length, second sequencing reactions were performed using M13R primer. To determine the genomic aberrations, each full-length sequence was mapped to hg18 using BLAT at a minimum of 90% identity as the cut-off.

The paired-end ditags were collected from three CLL samples. Genomic DNA from each sample was fractionated by *HindIII*digestion, which provides 3,561-bp resolution on average across the genome based on hg18 sequences \[[@B11]\]. Unique paired-end ditags of 272,193, 320,283, and 307,547 was collected from each CLL sample, covering 32%, 34% and 38% *HindIII*fragments in each CLL genome respectively. Comparing the three ditag sets shows that between 87,968 and 108,579 ditags are present between two CLL samples, and 51,632 ditags are commonly present in all three CLL samples (Table [1A](#T1){ref-type="table"}). The ditags present only in individual CLL sample could be the ditags representing individual genomic differences, the ditags potentially originating from experimental artifacts, or ditags detected in one but not in others due to unsaturated ditag collection in each CLL under the sequencing scale. The 51,632 ditags detected in all three CLL samples cover 5% of genomic DNA fragments commonly detected in the three CLL genomes. In order to provide high confidence for further downstream studies, we focused on the 51,632 common ditags for further mapping analysis. We compared the 51,632 common ditags with multiple known human genome sequences, including the human genome reference sequence hg18, human SNP, human GM15510 genome sequences, chimpanzee genome sequences that are highly homologous to the humans, Watson genome sequences, and Venter genome sequences. Of the 51,632 ditags used for the mapping, 98.3% (50,799) map to hg18 that represent normal genomic fragments in the CLL genomes, 0.4% (230) are unmapped ditags that represent potential genomic aberrations commonly present in all three CLL genomes, and the remaining ditags map to other genomes that represent normal genome variations (Table [1B](#T1){ref-type="table"}).

###### 

Paired-end tags collected from three CLL samples

  A. Ditag distribution in three CLL samples                                                   
  ------------------------------------------------------- -------------------- --------------- ---------------
                                                          **CLL sample (%)**                   
                                                                                               
                                                          **1**                **2**           **3**
                                                                                               
  Total sequence reads                                    231,941              321,290         268,124
  Total ditags                                            623,539              859,836         700,991
  Unique ditag                                            272,188 (100)        320,278 (100)   307,542 (100)
  Ditags common in two                                    99,815               99,815          
                                                          87,968                               87,968
                                                                               108,579         108,579
  Ditags common in three                                  51,632 (19)          51,632 (16)     51,632 (17)
                                                                                               
                                                                                               
  B. Mapping ditags to reference human genome sequences                                        
                                                                                               
                                                          Mapped (%)                           Unmapped (%)
                                                                                               
  Total common ditags                                     51,632 (100)                         
  HG18                                                    50,799 (98.3)                        833 (1.7)
  Homopolymer                                             22                                   816
  Chimpanzee genome                                       195                                  616
  Other human Genomes                                     386\*                                230
   GM15510 genome                                         28                                   
   Celera genome                                          165                                  
   Venter genome                                          352                                  
   Watson genome                                          61                                   
                                                                                               
  Total unmapped                                                                               230 (0.4)

\*These mapped to multiple genomes was counted only once.

To determine the types of genomic aberrations for the unmapped ditags, we generated full-length sequence for the restriction DNA fragment detected by the unmapped ditags by using the \"ditag-PCR\" method, in which the ditag sequences were used as PCR sense and antisense primers to amplify the original DNA fragment that derived the unmapped ditag. We performed 192 reactions in eight CLL samples including two used in ditag collection and six additional CLL samples. Under the conditions that a full-length sequence must be longer than 50 bases and detected at least in the CLL used in ditag collection or at least in two additional CLL samples, 220 full-length sequences were generated from 100 unmapped ditags. Mapping the full-length sequences to hg18 identified different types of genomic aberrations caused by insertion, deletion and base change. Many of these aberrations created new *HindIII*restriction site that leads to the release of unmapped ditag, or the change of ditag sequence composition that prevents ditag mapping. These aberrations were observed in both coding and non-coding regions in CLL genome. For example, aberrations were detected in exons of NEK8, RUNX1 and MUC2 genes, and introns of 20 other genes (Table [2A](#T2){ref-type="table"}, Additional file [2](#S2){ref-type="supplementary-material"}: Supplementary table S2). NEK8 encodes a member of the serine/threonine protein kinase family, which plays a role in cell cycle progression from G2 to M phase and is over-expressed in breast cancer \[[@B12]\]. A 353-base sequence converted from the unmapped ditag AAGCTTACCCTCTGGACGCCTGTATGAAGCTT maps to the last exon (Exon 15) coding for the 3\' UTR of NEK8. Two *HindIII*restriction sites were inserted in the sequence that are not present in the wild-type NEK8 gene. RUNX1 is a gene involved in AML through its involvement in the t(8;21) \[[@B13]\]. A 434-base full-length sequence from a ditag AAGCTTCGGCCTATAG/ACAACCTAACAAGCTT was detected in all eight CLL samples, and maps to intron 3 and exon 4 of RUNX1. Analyzing the mapped region shows a T to C single-base change between the sequence and exon 4 of RUNX1 gene. Searching dbSNP reveals that this is a SNP (rs1235270). Due to the uncertainty of RUNX1 protein coding sequence itself, it is not certain if this germline SNP causes a coding amino acid change. Several bases are also changed in the mapped intron 3 of RUNX1 gene. These base changes raise an interesting question whether RUNX1 could be involved in CLL. MUC2 is a member of the MUCIN family, which codes for high molecular weight glycoproteins. The abnormalities of MUC2 is linked with colorectal and pancreas cancer \[[@B14]\]. A 410-base sequence derived from an unmapped ditag AAGCTTCCGGTCGGCTTCGCAGTAGAAAGCTT covers intron 29, exon 30 and intron 30 of MUC2 gene. This sequence also contains two *HindIII*restriction sites AAGCTT inserted at both its ends that do not exist in the wild-type MUC2 gene. Only three aberrations were detected in the exon of three known genes. This could be attributed to the limited genome coverage of the study and the low percentage of the exon-coding sequences in the genome. With increased genome coverage, it would be possible to identify the aberrations affecting more exons.

###### 

Aberrations in exon and intron, and only present in CLL

  Ditag                                      Full-length (bp)\*   CLL Sample\*\*   **Chr**.   Location   Aberration   Gene                                                                                    
  ------------------------------------------ -------------------- ---------------- ---------- ---------- ------------ ------ ---- ---- ---- ---------- --------------------- ------------------------ ------- ------------
  A. Aberrations affecting exon and intron                                                                                                                                                                    
  AAGCTTACCCTCTGGACGCCTGTATGAAGCTT           353                  \+               \-         \-         \-           \-     \-   \-   \-   17q11.2    24093147-24093483     Insertion                NEK8    
                                             268                  \+               \+         \-         \-           \-     \-   \-   \-   19p13.2    10331021-10331266     Insertion                        TYK2
  AAGCTTCGGCCTATAGACAACCTAACAAGCTT           434                  \+               \+         \+         \+           \+     \+   \+   \-   21q22.12   35949034-35949460     Base change              RUNX1   
  AAGCTTCCGGTCGGCTTCGCAGTAGAAAGCTT           410                  \-               \+         \-         \+           \-     \-   \-   \-   11p15.5    1084558-1084956       Insertion                MUC2    MUC2
  AAGCTTGAGGGTGGAGTTCCTTCTGTAAGCTT           181                  \-               \+         \+         \-           \-     \-   \-   \-   2p11.2     87573183-87573358     Base change, insertion           BC070201
  AAGCTTGGCCAGAGACAGGCATCATGAAGCTT           116                  \+               \-         \-         \-           \-     \-   \-   \-   10q22.1    73213666-73213767     Base change                      CDH23
  AAGCTTGTGGACCACCGCTGTGAGTCAAGCTT           300                  \+               \+         \+         \+           \+     \-   \+   \+   20p12.3    6033711-6034006       Base change                      FERMT1
  AAGCTTCATATGAGGATCAAAAACGAAAGCTT           283                  \+               \+         \-         \+           \+     \+   \-   \-   3p14.2     61015245-61015527     Base change                      FHIT
  AAGCTTCTTTGTGATGCTCAGACATGAAGCTT           332                  \-               \+         \-         \-           \-     \+   \-   \-   11q23.3    120263755-120264067   Base change                      GRIK4
  AAGCTTAGATCAGTGAGCCTACGGCGAAGCTT           605                  \+               \+         \+         \+           \+     \+   \-   \+   16q22.2    69601759-69602345     Base change                      HYDIN
  AAGCTTCGCCGTGGGCTCACTGATCTAAGCTT           614                  \+               \+         \+         \-           \+     \+   \+   \+   16q22.2    69601760-69602350     Base change, insertion           HYDIN
  AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT           448                  \+               \-         \+         \-           \-     \-   \+   \+   5q22.2     112671099-112671541   Base change, insertion           MCC
  AAGCTTGCTTCTTTGCTGATACTGGCAAGCTT           582                  \-               \+         \+         \-           \-     \+   \-   \-   12q24.31   123563471-123564048   Base change, insertion           NCOR2
  AAGCTTGGCGTCAATCCACACCAAAGAAGCTT           349                  \-               \-         \-         \-           \+     \+   \-   \-   5q33.1     149870225-149870557   Insertion                        NDST1
                                             1306                 \-               \-         \-         \+           \-     \+   \-   \-   8q22.2     99587880-99589168     Base change, insertion           STK3
  AAGCTTGAAATAAGTGCTGCATCCTGAAGCTT           163                  \-               \+         \+         \-           \+     \-   \-   \-   2q32.1     182858618-182858771   Base change, insertion           PDE1A
  AAGCTTTCCTAGGGAGCTGGGTGGTGAAGCTT           638                  \-               \-         \-         \+           \+     \-   \-   \-   17q25.1    68849242-68849864     Insertion                        SDK2
                                             211                  \+               \-         \-         \-           \-     \-   \-   \-   9q34.11    129692280-129692481   Base change                      ST6GALNAC6
  AAGCTTGCAGAAGGGGAGCCAGGGTGAAGCTT           312                  \-               \-         \+         \-           \-     \-   \+   \-   2p25.3     3382092-3382390       Insertion                        TTC15
                                             187                  \+               \-         \-         \-           \-     \+   \+   \-   13q12.13   26098258-26098437     Base change, insertion           WASF3
  AAGCTTCAGGAAAGTCCACTAGCAAAAAGCTT           197                  \+               \+         \+         \+           \+     \+   \+   \-   9p13.3     33972115-33972294     Insertion                        UBAP2
                                             112                  \+               \-         \-         \-           \-     \-   \-   \-   9p13.3     33972115-33972294     Insertion                        UBAP2
                                             170                  \+               \-         \-         \-           \-     \-   \-   \-   9p13.3     33972115-33972294     Insertion                        UBAP2
  AAGCTTTAATGACTGAGGGGTTCTCAAAGCTT           1147                 \+               \+         \+         \-           \+     \-   \+   \-   6q25.3     157931989-157933131   Base change                      ZDHHC14
  AAGCTTTGAGAACCCCTCAGTCATTAAAGCTT           1134                 \+               \+         \-         \-           \-     \-   \+   \-   6q25.3     157931989-157933131   Base change                      ZDHHC14
  AAGCTTGCACAAGGGGCCCCTTGTGCAAGCTT           691                  \+               \-         \-         \-           \-     \-   \-   \-   4p16.3     2372796-2373473       Insertion                        ZFYVE28
                                                                                                                                                                                                              
  B. Sequences only present in CLL genome                                                                                                                                                                     
  AAGCTTGATATCGTGATCACCTTAAGAAGCTT           332                  \-               \+         \+         \-           \-     \-   \-   \-   \-         \-                    \-                       \-      \-
  AAGCTTAGATAGAGCGCAGTCAACTGAAGCTT           107                  \+               \+         \+         \+           \+     \+   \+   \+   \-         \-                    \-                       \-      \-
  AAGCTTCCGGTCGGCTTCGCAGTAGAAAGCTT           159                  \+               \+         \+         \+           \-     \+   \-   \-   \-         \-                    \-                       \-      \-
  AAGCTTCTCATCCTTCACCTTGGTCGAAGCTT           182\*\*\*            \+               \-         \-         \-           \-     \-   \-   \-   \-         \-                    \-                       \-      \-
                                             540                  \-               \+         \-         \-           \-     \-   \+   \+   \-         \-                    \-                       \-      \-
                                             362                  \-               \-         \-         \-           \-     \-   \+   \+   \-         \-                    \-                       \-      \-
  AAGCTTGAAAAAGGTTCAGGCAAACTAAGCTT           84                   \+               \-         \-         \-           \-     \-   \-   \-   \-         \-                    \-                       \-      \-
  AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT           923                  \-               \-         \+         \-           \-     \+   \-   \+   \-         \-                    \-                       \-      \-
  AAGCTTGGCGTCAATCCACACCAAAGAAGCTT           347                  \-               \+         \+         \-           \-     \-   \-   \+   \-         \-                    \-                       \-      \-
  AAGCTTTCTTGATAAGGCTCCTACGCAAGCTT           250                  \-               \+         \-         \-           \-     \-   \-   \+   \-         \-                    \-                       \-      \-

\*A full-length sequence must be detected in at least one of the two CLL sampes used in ditag collection, or at least in one other CLL samples.

\*\* Sample \#1 and 2 were used for ditag collection.

\*\*\*tag1 part map to chr1:56672307-56672331

Aberrations also affect the introns of multiple genes. FHIT encodes diadenosine 5\',5\'\'\'-P1,P3-triphosphate hydrolase involved in purine metabolism \[[@B15]\]. It is located in the common fragile site FRA3B on chromosome 3, where carcinogen-induced damage can lead to translocations in several cancers. A 283-base sequence maps to intron 8 of FHIT gene but its tag 1 contains GA to TG change. HYDIN encodes an axonemal protein; mutation of HYDIN is related to congenital hydrocephalus \[[@B16]\]. Two full-length sequences of 605-bp and 614-bp from two different unmapped ditags were obtained from seven CLL samples. Both sequences map to 21st intron of HYDIN. The 605-bp sequence contains CCTACGGCG in its tag 2 converted from wild-type gCcACaGCa (lowercase refers to the changed base), and the 614-bp sequence contains CGCC converted from wild-type tGCt in its tag 1 and an internal insertion. NCOR2 is a transcriptional regulator that recruits histone deacetylases to promoters \[[@B17]\]. A 582-base sequence maps to intron 1 of NCOR2, but its tag 1 contains an AAGC insertion, and tag 2 contains a C to T change, an AG deletion, and a T insertion. TYK2 is a member of the JAK family involving in IFN-g, IL-6, IL-10 and IL-12 signaling. Mutation in this gene is associated with hyperimmunoglobulin E syndrome \[[@B18]\]. A 268-base sequence maps to intron 14 of TYK2 but its tag 1 contains an AAGCTTA insertion and its tag 2 contains a TGAAGCTT insertion. Both insertions create *HindIII*restriction sites that lead to the generation of the unmapped ditag. A 197-base sequence was detected in seven CLL samples and two different sequences of 112-base and 170-base were generated from the CLL used in ditag collection. All three sequences map to *UBAP2*located at 9p13.3, a gene involved in the ubiquitination pathway \[[@B19]\]. For the 197-base sequence, its 178 bases map to intron 6 of *UBAP2*gene and the remaining 18 bases have no map, whereas the 112-base and 170-base sequences contain different insertions. Although the aberrations in many of these genes have been correlated with different types of cancer, most have not been linked with CLL.

Non-coding regions contribute to the majority of the genome, and contain important functional elements involving DNA replication, genome stability, regulation of gene expression, and coding for non-coding transcripts etc. Extensive characterization of non-coding region could provide rich candidate markers for clinical applications and identify the hotspots of genomic aberrations involving cancer development. A total of 37 sequences generated from 30 unmapped ditags mapped to the non-coding regions in the genome with various types of abnormalities (Table [3](#T3){ref-type="table"}, Additional file [3](#S3){ref-type="supplementary-material"}: Supplemental Table S3). Although these loci are not directly located in the coding regions, many genes are located nearby the mapped locations. Of the 26 loci specifically mapped by the sequences, 15 have genes located either upstream, downstream or both within 100 kb distance. For example, a 614 base sequence maps to 5q35.1 between169443856-169444467, where DOCK2 is located 27,836 base upstream and FOXI1 is located 21028 downstream. A 398-base sequence maps to 15q26.1 between 88110782 and 88111168, where two homologous transcriptional factor genes, MESP1 and MESP2, are located 16,678-base upstream and 9,425-base downstream correspondingly. microRNA gene MIR663 are located 20,580 base upstream of 20p11.1 between 26157494-26158252 mapped by a 920-base sequence detected in seven CLL samples. Another microRNA gene MIR663B is located 10,964-base upstream of 2q21.2 between 132742087-132742356 mapped by a 290-base sequence, of which a non-coding RNA gene NCRNA00164 is located in between. The aberrations could affect the nearby genes through influencing the regulation of gene expression.

###### 

Aberrations in the intergenic region

  Ditag                              FullL-length (bp)   CLL sample   **chr**.   Location   Aberration   Nearby genes                                                                                                                            
  ---------------------------------- ------------------- ------------ ---------- ---------- ------------ -------------- ---- ---- ---- ---------- --------------------- ------------------------ ------------------- ---------------- ---------- --------
  AAGCTTACTTTCTCGGTTCCATTACTAAGCTT   614                 \-           \-         \+         \-           \-             \+   \+   \-   5q35.1     169443856-169444467   Base change              DOCK2               27,836           FOXI1      21,028
  AAGCTTAGCCGGGCATCCTCTTTCCTAAGCTT   427                 \-           \-         \-         \-           \-             \-   \+   \+   17q25.1    68688801-68689216     Base change              SSTR2               16,046           COG1       11,552
                                     398                 \-           \+         \+         \-           \-             \-   \-   \-   15q26.1    88110782-88111168     Insertion, base change   MESP1               16,678           MESP2      9,425
  AAGCTTAGTTTGGCTGCATGAGACTGAAGCTT   737                 \-           \-         \+         \-           \-             \-   \-   \+   16q23.1    74682385-74683114     Base change                                                              
  AAGCTTATGATGATCCCCTGAGCTAAAAGCTT   358                 \+           \-         \-         \-           \-             \-   \-   \-   1q23.3     162264795-162265148   Insertion, base change                                                   
                                     264                 \+           \-         \-         \-           \-             \-   \-   \-   5p15.33    2449552-2449774       Insertion                                                                
  AAGCTTCAACGATAGTTCATCATCATAAGCTT   265                 \-           \+         \+         \-           \-             \-   \-   \-   16p13.3    808762-808956         Base change              PRR25               4,900            LMF1       34,679
  AAGCTTCAATAGCCGAAGCCAAACTAAAGCTT   556                 \+           \+         \-         \-           \+             \+   \+   \-   12q15      66234005-66234554     Base change                                                   DYRK2      94,467
  AAGCTTCACTCAGTCATATGGCATGGAAGCTT   130                 \-           \-         \-         \-           \-             \+   \+   \-   10q26.3    133154300-133154419   Insertion                                                                
  AAGCTTCACTGCAGCTATAACACTGCAAGCTT   920                 \+           \+         \+         \+           \+             \+   \-   \+   20p11.1    26157494-26158252     Insertion, base change   MIR663              20,580                      
  AAGCTTCCTCTGTACTCACATTAACGAAGCTT   892                 \-           \+         \+         \-           \-             \+   \+   \-   9q12       67914079-67914963     Base change                                                              
  AAGCTTGAAATAAGTGCTGCATCCTGAAGCTT   606                 \+           \-         \-         \-           \-             \-   \-   \-   1q41       220652161-220652760   Insertion, base change                                                   
                                     252                 \-           \-         \+         \-           \-             \-   \-   \+   20q13.13   46025615-46025861     Base change                                                              
  AAGCTTGACTCATTGCGTCTTATTCTAAGCTT   1060                \+           \-         \-         \-           \-             \-   \-   \-   9q22.31    94477651-94478404     Insertion                IPPK                5,283            BICD2      35,062
  AAGCTTGCACAAGGGGCCCCTTGTGCAAGCTT   606                 \+           \-         \-         \-           \-             \-   \-   \-   2q35       220216964-220217558   Insertion                SLC4A3              16,038                      
  AAGCTTGCAGAAGGGGAGCCAGGGTGAAGCTT   553                 \-           \-         \-         \+           \-             \-   \-   \+   11q23.2    115071517-115072057   Insertion                                                                
  AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT   758                 \-           \-         \-         \+           \+             \-   \-   \-   13q12.3    30403963-30404714     Insertion, base change   C13orf33            25,635           C13orf26   120
                                     602                 \+           \+         \+         \-           \+             \-   \-   \+   1q42.13    227318140-227318732   Insertion                                                                
  AAGCTTGGAGCCCTAGCCACAATTGTAAGCTT   1453                \-           \+         \-         \-           \+             \+   \+   \-   13q21.33   70285628-70287080     Base change                                                              
  AAGCTTGGCCAGAGACAGGCATCATGAAGCTT   900                 \+           \-         \+         \+           \-             \+   \-   \+   6q23.2     135162469-135163363   Base change                                                              
  AAGCTTTCACTTCATTGGAGTCAGTGAAGCTT   322                 \+           \+         \+         \-           \+             \+   \+   \-   13q14.12   44367511-44367832     Base change                                                   NUFIP1     43,552
  AAGCTTTCCTAGGGAGCTGGGTGGTGAAGCTT   290                 \-           \-         \+         \-           \-             \-   \+   \-   2q21.2     132742087-132742356   Insertion                NCRNA00164MIR663B   10,075; 10,964              
                                     120                 \+           \-         \-         \-           \-             \-   \-   \-   4p15.33    14280120-14280230     Insertion, base change                                                   
  AAGCTTTCCTTTTCCTTCTGCTCTTAAAGCTT   1071                \+           \-         \+         \-           \-             \+   \-   \-   6q27       164534304-164535365   Base change                                                              
  AAGCTTTGCATTGGCAGAAGCCACCAAAGCTT   1039                \-           \+         \-         \-           \-             \-   \+   \-   9q12       69920049-69921093     Base change                                                              
  AAGCTTTTAAGGGATCATGCCTCTCCAAGCTT   1534                \+           \-         \+         \-           \+             \+   \+   \-   1q21.2     148015439-148016961   Base change                                                   FCGR1A     3,951
  AAGCTTACCCTCTGGACGCCTGTATGAAGCTT   185                 \+           \-         \-         \-           \-             \-   \-   \-   9q22.33    100893873-100893975   Insertion                                                     TGFBR1     13,258

One hundred and forty seven full-length sequences converted from 57 unmapped tags map to the highly repetitive sequences in the non-coding regions. Of these sequences, 110 sequences map to the ALR/Alpha satellite sequences of the centromere, and chromosome 2, 10, and 17 are among the most frequent ones (Table [4](#T4){ref-type="table"}, Additional file [4](#S4){ref-type="supplementary-material"}: Supplemental Table S4): 23 sequences converted from 13 unmapped tags map to the centromere of chromosome 2 at 2p11.1, 41 sequences converted from 16 ditags map to the centromere of chromosome 10 at 10q11.1, and 22 sequences converted from 6 unmapped ditags map to the centromere of chromosome 17 at 17p11.1. The presence of highly frequent aberrations in ALR/Alpha satellite sequences in these three chromosomes suggests that these could be the hot spot of genomic aberrations in CLL. Aberrations in repetitive sequences have been shown to contribute to cancer development \[[@B20]\]. However, it is difficult to analyze the aberrations in these highly repetitive regions using the hybridization-based approach due to the difficulty to designing specific probes. Our results show that restriction sequencing-based approach provides a useful tool to study the aberrations in these regions.

###### 

Aberrations in the centromere region

  Ditag                              Full-length (bp)   CLL sample   **Chr**.   Location   Sequence type                                                       
  ---------------------------------- ------------------ ------------ ---------- ---------- --------------- ---- ---- ---- ---- --------- --------------------- -------------
  AAGCTTTCATTGGGATAACAGTGTTGAAGCTT   562                \-           \+         \+         \-              \-   \+   \+   \+   2p11.1    132722630-132722850   ALR/Alpha
                                     893                \-           \+         \-         \-              \-   \-   \+   \-   2p11.1    91677156-91682632     ALR/Alpha
                                     217                \+           \+         \-         \+              \-   \-   \+   \-   2p11.1    91677835-91680254     ALR/Alpha
  AAGCTTTCCAGTTAAGCTTTCTGGGGAAGCTT   1067               \+           \+         \+         \+              \+   \+   \+   \-   2p11.1    91257036-91258039     
                                     1002               \+           \-         \-         \-              \-   \-   \+   \-   2p11.1    91257036-91258039     
  AAGCTTCTTTATGAGGAACAGTGTTGAAGCTT   216                \+           \+         \+         \+              \-   \-   \+   \-   2p11.1    91670531-91670746     ALR/Alpha
                                     896                \+           \+         \-         \+              \-   \-   \-   \-   2p11.1    91670531-91686712     ALR/Alpha
                                     901                \+           \-         \-         \-              \-   \-   \+   \-   2p11.1    91670531-91686712     ALR/Alpha
                                     560                \+           \-         \-         \-              \+   \-   \-   \-   2p11.1    91655191-91672448     ALR/Alpha
                                     2231               \-           \-         \-         \-              \+   \+   \-   \-   2p11.1    91670550-91684334     ALR/Alpha
  AAGCTTCTGAGAATGCCATCCCAATGAAGCTT   686                \+           \-         \-         \-              \-   \-   \+   \-   2p11.1    91677155-91689898     ALR/Alpha
  AAGCTTATTTGAGATGAAAGGAGTAGAAGCTT   1234               \+           \+         \-         \-              \-   \-   \-   \-   2p11.1    91664565-91688410     ALR/Alpha
                                     726                \+           \+         \+         \+              \+   \+   \+   \-   2p11.1    91676309-91680254     ALR/Alpha
  AAGCTTCAACACTGTTGTTCCCAATGAAGCTT   612                \-           \+         \+         \-              \-   \+   \-   \-   2p11.1    91676431-91689428     ALR/Alpha
  AAGCTTCAATGGGATGAAGAGTGTTGAAGCTT   556                \+           \+         \+         \-              \+   \+   \+   \-   2p11.1    91684461-91685014     ALR/Alpha
                                     894                \-           \-         \+         \-              \-   \-   \+   \-   2p11.1    91677156-91680254     ALR/Alpha
  AAGCTTCAATTGGGATAACAGTGTTGAAGCTT   555                \-           \-         \-         \+              \-   \+   \+   \+   2p11.1    91677836-91680592     ALR/Alpha
  AAGCTTCATTAGGGATAACAGTGTTGAAGCTT   555                \+           \+         \-         \-              \-   \+   \-   \-   2p11.1    91677156-91677709     ALR/Alpha
  AAGCTTCATTGGGAACAACAGTGTTGAAGCTT   269                \-           \+         \-         \-              \-   \-   \+   \-   2p11.1    91677155-91677709     ALR/Alpha
  AAGCTTCATTGGGATGGCATTCTCAGAAGCTT   685                \+           \-         \-         \-              \-   \-   \-   \-   2p11.1    91674610-91684466     ALR/Alpha
  AAGCTTCTATTGGGATAACAGTGTTGAAGCTT   556                \+           \+         \+         \-              \-   \+   \+   \+   2p11.1    91672232-91680592     ALR/Alpha
                                     893                \-           \+         \-         \-              \-   \-   \+   \+   2p11.1    91653836-91682632     ALR/Alpha
  AAGCTTGACTCATTGCGTCTTATTCTAAGCTT   1179               \-           \+         \+         \+              \+   \+   \+   \-   2p11.1    91031886-91033063     ERVL-B4-int
  AAGCTTAAAACTCCTTTATGAAAAGAAAGCTT   637                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41848823-41861037     ALR/Alpha
  AAGCTTAAACTCCGTGCATCAAAAGAAAGCTT   689                \+           \+         \-         \-              \-   \-   \+   \-   10q11.1   41718813-41720661     ALR/Alpha
                                     1407               \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718474-41727608     ALR/Alpha
                                     601                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718888-41720661     ALR/Alpha
  AAGCTTAAACTTCTTGTATGAAAAGAAAGCTT   2067               \-           \+         \+         \-              \-   \-   \+   \-   10q11.1   41847790-41864775     ALR/Alpha
                                     1023               \+           \+         \-         \-              \-   \-   \-   \-   10q11.1   41718797-41729299     ALR/Alpha
                                     970                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41850170-41864775     ALR/Alpha
                                     346                \+           \-         \-         \-              \-   \-   \+   \-   10q11.1   41718460-41719477     ALR/Alpha
  AAGCTTCAACGCTGCGCTATTGAAGGAAGCTT   345                \-           \+         \+         \-              \-   \-   \-   \-   10q11.1   41726415-41729786     ALR/Alpha
                                     860                \+           \+         \+         \+              \+   \+   \+   \+   12p11.1   34724897-34729300     ALR/Alpha
  AAGCTTCAACTCTGTCCGCCTAAAGGAAGCTT   175                \-           \-         \-         \-              \+   \-   \+   \-   10q11.1   41719301-41720316     ALR/Alpha
  AAGCTTCAACTCTGTGCATTGGCCTCAAGCTT   279                \+           \+         \+         \+              \+   \+   \+   \+   10q11.1   41849321-41850275     ALR/Alpha
                                     622                \+           \+         \+         \+              \-   \+   \+   \-   10q11.1   41849321-41858079     ALR/Alpha
                                     619                \-           \+         \-         \-              \-   \+   \+   \-   10q11.1   41849321-41861137     ALR/Alpha
  AAGCTTCAACTCTGTGCCGCTAAAGGAAGCTT   344                \-           \+         \+         \-              \+   \+   \+   \+   10q11.1   41718623-41720492     ALR/Alpha
                                     2280               \+           \-         \-         \-              \-   \+   \-   \-   10q11.1   41717944-41720994     ALR/Alpha
                                     1359               \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41717944-41729975     ALR/Alpha
                                     1190               \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718623-41720492     ALR/Alpha
                                     681                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41720147-41729975     ALR/Alpha
  AAGCTTCCTTCAGAAACAAGGAGTTTAAGCTT   858                \+           \-         \+         \-              \+   \+   \+   \-   10q11.1   41718623-41720661     ALR/Alpha
  AAGCTTCCTTTTAGGCCACAGAGTTGAAGCTT   348                \-           \+         \+         \-              \-   \-   \-   \-   10q11.1   41719301-41720492     ALR/Alpha
                                     1029               \-           \+         \+         \-              \-   \-   \-   \-   10q11.1   41847960-41861361     ALR/Alpha
                                     684                \+           \-         \-         \-              \-   \-   \+   \-   10q11.1   41718622-41721845     ALR/Alpha
  AAGCTTCCTTTTCATACAAGGAGTTTAAGCTT   1498               \-           \+         \-         \-              \-   \+   \-   \-   10q11.1   41718461-41720661     ALR/Alpha
  AAGCTTCTTTTTCATGCAAGGAGTTTAAGCTT   385                \+           \-         \-         \-              \+   \+   \+   \-   10q11.1   41718767-41719477     ALR/Alpha
                                     724                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718767-41720661     ALR/Alpha
                                     722                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41847452-41858698     ALR/Alpha
  AAGCTTTCCTTTAGGCCACAGAGTTGAAGCTT   1904               \-           \+         \+         \-              \-   \-   \-   \-   10q11.1   41847960-41863582     ALR/Alpha
                                     345                \-           \-         \+         \+              \-   \-   \+   \-   10q11.1   41720491-41722352     ALR/Alpha
  AAGCTTTCTTTTTCATCAAGGAGTTTAAGCTT   386                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41720293-41720661     ALR/Alpha
  AAGCTTTGAAATCTCCCACCTAAAGGAAGCTT   408                \+           \-         \+         \+              \+   \+   \+   \-   10q11.1   41718623-41722413     ALR/Alpha
                                     750                \-           \-         \+         \+              \-   \-   \-   \-   10q11.1   41847563-41863586     ALR/Alpha
                                     1262               \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718623-41720552     ALR/Alpha
  AAGCTTTTCTTTTCATCAAGGAGTTTAAGCTT   1379               \-           \-         \+         \-              \-   \-   \+   \-   10q11.1   41718797-41720661     ALR/Alpha
                                     691                \-           \-         \+         \-              \-   \+   \-   \-   10q11.1   41718460-41720661     ALR/Alpha
                                     2041               \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41847790-41866145     ALR/Alpha
                                     832                \+           \-         \-         \-              \-   \-   \-   \-   10q11.1   41718460-41720661     ALR/Alpha
                                     347                \-           \-         \-         \+              \-   \+   \+   \-   10q11.1   41718460-41720661     ALR/Alpha
                                     1024               \+           \+         \-         \-              \-   \+   \+   \-   10q11.1   41718117-41720661     ALR/Alpha
  AAGCTTTTGAGGCCAACACAGAGTTGAAGCTT   620                \-           \+         \-         \-              \-   \+   \+   \+   10q11.1   41849321-41855026     ALR/Alpha
                                     281                \+           \+         \-         \-              \-   \-   \-   \-   10q11.1   41849321-41850276     ALR/Alpha
  AAGCTTCCTGTGATGATTCGAGAGAGAAGCTT   1419               \+           \+         \-         \-              \+   \+   \-   \-   17p11.1   22175465-22179262     ALR/Alpha
                                     576                \-           \-         \-         \-              \-   \+   \+   \+   17p11.1   22182601-22184019     ALR/Alpha
                                     1966               \+           \-         \+         \-              \-   \-   \-   \-   17p11.1   22175465-22186396     ALR/Alpha
                                     2314               \-           \-         \+         \-              \-   \+   \-   \-   17p11.1   22173089-22186396     ALR/Alpha
                                     234                \+           \+         \+         \+              \-   \+   \-   \+   17p11.1   22170709-22172128     ALR/Alpha
                                     578                \+           \+         \+         \-              \-   \+   \-   \+   17p11.1   22176307-22179262     ALR/Alpha
                                     1090               \-           \+         \-         \-              \-   \-   \+   \+   17p11.1   22170709-22179262     ALR/Alpha
  AAGCTTTCTCTCTCGACATCACAGAGAAGCTT   641                \+           \-         \-         \-              \-   \-   \-   \-   17p11.1   22178721-22179262     ALR/Alpha
                                     1389               \+           \-         \-         \-              \-   \-   \-   \-   17p11.1   22175464-22184019     ALR/Alpha
                                     1824               \+           \-         \-         \-              \-   \-   \-   \-   17p11.1   22175464-22181640     ALR/Alpha
                                     579                \-           \+         \-         \-              \+   \+   \+   \-   17p11.1   22170709-22179262     ALR/Alpha
                                     1420               \-           \+         \+         \-              \+   \+   \-   \-   17p11.1   22180222-22184019     ALR/Alpha
  AAGCTTCTCTCTCGAACATCGCAGAGAAGCTT   1091               \+           \-         \-         \-              \-   \+   \-   \+   17p11.1   22173083-22184019     ALR/Alpha
                                     749                \-           \-         \+         \-              \-   \-   \-   \+   17p11.1   22183291-22184019     ALR/Alpha
  AAGCTTCTCTGAGATGTTCGAGAGAGAAGCTT   579                \+           \+         \+         \+              \-   \-   \+   \+   17p11.1   22181236-22184019     ALR/Alpha
                                     918                \+           \+         \+         \-              \-   \-   \-   \-   17p11.1   22173087-22184019     ALR/Alpha
                                     407                \-           \+         \-         \+              \-   \+   \-   \-   17p11.1   22174101-22184019     ALR/Alpha
                                     406                \-           \-         \+         \-              \-   \-   \-   \+   17p11.1   22175464-22176883     ALR/Alpha
                                     1087               \+           \-         \-         \-              \-   \-   \-   \-   17p11.1   22175459-22181640     ALR/Alpha
  AAGCTTCTGAGAATGCTTTTCTGAAAAAGCTT   355                \+           \+         \-         \-              \+   \+   \+   \-   17p11.1   22184624-22184977     ALR/Alpha
                                     1037               \+           \-         \-         \-              \-   \-   \-   \-   17p11.1   22184624-22186848     ALR/Alpha
  AAGCTTTGAGACCTGTCTCAGAGTTGAAGCTT   799                \+           \+         \+         \-              \+   \+   \+   \-   17p11.1   21687309-21687527     ALR/Alpha

Ten full-length sequences generated from eight unmapped ditags did not map to known human genome sequences (Table [2B](#T2){ref-type="table"}. Additional file [5](#S5){ref-type="supplementary-material"}: Supplementary table S5). For example, a 107-base full-length sequence converted from an unmapped ditag AAGCTTAGATAGAGCGCAGTCAACTGAAGCTT was detected in all eight CLL samples. However, it does not map to the reference genome sequences. These sequences represent the DNA contents present in CLL genomes but not in normal genomes.

Through high-resolution scanning of three CLL genomes and verifying the results using full-length sequences and additional CLL genomes, our study provides evidence showing the wide presence of genomic aberrations in CLL, of which most are small lesions. Studies with increased number of CLL samples and at high genome coverage will be required to better understand the genetic aberrations in CLL. Although the study used multiple genomics databases to eliminate the changes from normal genomic polymorphism, further studies with normal DNA from the same patient will be required to fully distinguish somatic mutations from germline variations in CLL.
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